## 2017 PD THERAPEUTICS CONFERENCE

The Michael J. Fox Foundation for Parkinson’s Research  
11th Annual Parkinson’s Disease Therapeutics Conference  
October 30, 2017  
New York, NY

### CONFERENCE PROGRAM

All presentations are followed by Q&A.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45</td>
<td>BREAKFAST</td>
</tr>
<tr>
<td>8:30 – 9:00</td>
<td>WELCOME BY TODD SHERER, PhD AND DAVID STANDAERT, PhD</td>
</tr>
<tr>
<td>9:00 – 10:40</td>
<td>EMERGING TARGETS ADVANCING TREATMENTS</td>
</tr>
<tr>
<td>10:40 – 11:10</td>
<td>NETWORKING BREAK/POSTER VIEWING</td>
</tr>
<tr>
<td>11:10 – 12:00</td>
<td>PROGRESS IN THE PIPELINE</td>
</tr>
<tr>
<td>12:00 – 1:00</td>
<td>LUNCH/POSTER VIEWING</td>
</tr>
</tbody>
</table>

#### EMERGING TARGETS ADVANCING TREATMENTS

- **TRENT MARTIN WOODRUFF, PhD, The University of Queensland**  
  “Therapeutic Targeting of the NLRP3 Inflammasome for Parkinson’s Disease”

- **PAUL THOMPSON, PhD, Mission Therapeutics Inc.**  
  “Validation of USP30 as a Therapeutic Target for Parkinson’s Disease Modification”

- **DARREN MOORE, PhD, Van Andel Research Institute**  
  “VPS35 as a Novel Target for Parkinson’s Disease: Models and Mechanisms”

- **DAVID SULZER, PhD, Columbia University**  
  “Roles for Autoimmunity in Parkinson’s Disease”

#### PROGRESS IN THE PIPELINE

- **THOMAS FOLTYNIE, PhD, MD, MRCO, University College London**  
  “Exenatide as a Treatment for Patients with Parkinson’s Disease”

- **BERNARD RAVINA, MD, MS, Voyager Therapeutics**  
  “AADC Gene Therapy for Advanced Parkinson’s Disease”
1:00 – 2:15 TRACKING PROGRESS IN TRACKING PARKINSON’S

**EDILIO BORRONI, PhD, F. Hoffman-LaRoche**
“Development of PET Tracers for Imaging of Alpha-synuclein Aggregates”

**BRIT MOLLENHAUER, MD, Paracelsus-Elena-Klinik**
“Biological Analyses of PPMI Samples”

**ANDREW SINGLETON, PhD, NIH National Institute on Aging**
“Data Driven Analyses in PPMI”

2:15 – 2:45 NETWORKING BREAK/POSTER VIEWING

2:45 – 4:00 HOT TOPICS IN PARKINSON’S DISEASE RESEARCH

**D. JAMES SURMEIER, PhD, Feinberg School of Medicine, Northwestern University**
“Therapeutic Implications of Selective Neuronal Vulnerability in Parkinson’s Disease”

**THOMAS GASSER, MD, PhD, University of Tubingen**
“Linking Parkinson’s Disease Genetic Targets within Idiopathic Parkinson’s Disease”

4:00 – 4:15 CLOSING REMARKS

4:15 – 6:00 COCKTAIL RECEPTION/POSTER VIEWING